However, at OTC dosages, the risk is lower as compared to prescription doses, and elevated risks identified in large cohort studies often did not reach statistical significance, including in participants with higher baseline risks.
← all excerpts
What a pain in the … back: a review of current treatment options with a focus on naproxen sodium.
1
—
—